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Michael J. Blahae, f, Roger S. Blumenthale, Raquel D. Conceicaog, Jose A.M. Carvalhog,
Raul D. Santosg, h, Khurram Nasiri

Abstract
Background: Serum gamma-glutamyl transferase (GGT) is a marker
of oxidative stress, associated with increased cardiovascular (CV)
risk. The impact of smoking on oxidative stress may be aggravated
in individuals with non-alcoholic fatty liver disease (NAFLD). We
aimed to ascertain the association of smoking on GGT levels in the
presence or absence of NAFLD.
Methods: We evaluated 6,354 healthy subjects (43 ± 10 years, 79%
males) without clinical cardiovascular disease (CVD) undergoing an
employer-sponsored physical between December 2008 and December 2010. NAFLD was diagnosed by ultrasound and participants were
categorized as current or non-smokers by self report. A multivariate
linear regression of the cross-sectional association between smoking
and GGT was conducted based on NAFLD status.
Results: The prevalence of NAFLD was 36% (n = 2,299) and 564
(9%) were current smokers. Smokers had significantly higher GGT
levels in the presence of NAFLD (P < 0.001). After multivariable
adjustment, current smoking was associated with 4.65 IU/L higher
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GGT level, P < 0.001, compared to non-smokers. When stratified by
NAFLD, the magnitude of this association was higher in subjects
with NAFLD (β-coefficient: 11.12; 95% confidence interval (CI):
5.76 - 16.48; P < 0.001); however, no such relationship was observed
in those without NAFLD (β: -0.02; 95% CI: -3.59, 3.56; P = 0.992).
Overall the interaction of NAFLD and smoking with GGT levels as
markers of oxidative stress was statistically significant.
Conclusions: Smoking is independently associated with significantly
increased oxidative stress as measured by GGT level. This association
demonstrates effect modification by NAFLD status, suggesting that
smoking may intensify CV risk in individuals with NAFLD.
Keywords: Gamma-glutamyl transferase; Oxidative stress; Non-alcoholic fatty liver disease; Smoking; Cardiovascular risk

Introduction
Oxidative stress plays a crucial role in cardiovascular disease
(CVD) mediating the pathway to atherosclerosis and inflammation [1, 2]. The oxidative stress theory is based on the assumption that the initial phase of atherosclerosis is dependent
on low-density lipoprotein (LDL) oxidative modifications [3].
Gamma-glutamyl transferase (GGT) is a biomarker secreted mostly by the liver and found in epithelial cells of humans. It plays an important role in glutathione metabolism, an
important component of the anti-oxidative process [4, 5]. This
marker has been implicated in atherosclerosis, diabetes, metabolic syndrome and increased cardiovascular (CV) risk [6-16].
Elevated GGT levels have also been linked with hepatic steatosis (HS) and liver cancer [14, 17]. While non-alcoholic fatty
liver disease (NAFLD) is the leading cause of chronic liver
disease in the western world, evidence has also shown it as an
independent risk factor for CVD [18, 19].
Similarly, it has been established that cigarette smoking
is an important risk factor for atherosclerosis and associated
with significant vascular disease [20-23]. Smoking enhances
the production of reactive oxygen species which promotes oxidative stress and lipid peroxidation [24-27]. While smoking is
associated with oxidative stress, its influence on GGT levels
in individuals with NAFLD is not clearly defined. Our study
examines the effect of the presence of NAFLD on the associa-
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tion between smoking and oxidative stress by GGT levels in an
asymptomatic population.

Materials and Methods
A total of 6,354 asymptomatic men and women, free of CVD,
who had an obligatory clinical and laboratory health evaluation from December 2008 to December 2010 at the Preventive
Medicine Center of the Albert Einstein Hospital in Sao Paulo,
Brazil were evaluated. The examination protocol has been previously described in prior publications [28]. Individuals were
provided with questionnaires for self-reported details of their
demographics, medical history, quantitative alcohol consumption, smoking status and medication usage during their clinical
visits. We excluded 110 individuals with missing information
of either smoking status, GGT levels and presence of steatosis.
Individuals with an established history of liver disease were
also excluded. Individual smoking status was defined as either current smoker or non-smoker. While current smoker was
defined as smoking at least one cigarette in the last 1 month,
non-smoker was one who did not smoke in the last month. Diabetes mellitus was identified by a previous physician diagnosis
or the use of glucose-lowering medication. Hypertension and
dyslipidemia were ascertained by a previous history or the use
of medications. Blood pressure measurements were made using an aneroid sphygmomanometer using the recommended
method from the American Heart Association [29]. The waist
circumference was the smallest diameter between the iliac
crest and the costal margin using a plastic anthropometric tape.
All blood specimens were collected after an overnight
fast. Plasma lipid, glucose, GGT and liver transaminase levels
(alanine aminotransferase (ALT) and aspartate aminotransferase (AST)) levels were measured by standardized automated laboratory tests using a Vitros platform (Johnson & Johnson
Clinical Diagnostics, New Brunswick, New Jersey). High-sensitivity C-reactive protein (hs-CRP) levels were determined
by immunonephelometry (Dade-Behring GMbH, Mannhein,
Germany). All tests were performed at the Central Laboratory
of the Albert Einstein Hospital.
NAFLD was diagnosed after at least a 6-h fast using an
ACUSON XP-10 device (Mountain View, CA) and was identified by the presence of an ultrasonographic pattern of a bright
liver, with evident contrast between hepatic and renal parenchyma and using a standardized algorithm (indicating HS) [30,
31]. Obesity was defined as a body mass index (BMI) of greater
than 30 kg/m2. The metabolic syndrome (MS) was defined using
criteria from the American Heart Association/National Heart,
Lung, and Blood Institute published scientific statement on the
metabolic syndrome [32]. Patients with ≥ 3 of the following
risks were classified as having the MS: truncal obesity (≥ 102
cm (40 inches) for men and ≥ 88 cm (36 inches) for women),
high blood pressure (blood pressure ≥ 130/85 mm Hg or the use
of antihypertensive medications), hyperglycemia (fasting blood
glucose ≥ 100 mg/dL), low high-density lipoprotein cholesterol
(HDL-C) (≤ 40 mg/dL for men and ≤ 50 mg/dL for women)
and hypertriglyceridemia (≥ 150 mg/dL) [32]. This study did not
involve any animal study and appropriate IRB approval was obtained prior to the administration of surveys to the participants.

All data were de-identified prior to analysis and determined not
to meet criteria for protected health information (PHI) [28].
Baseline characteristics of individuals with a combination
of the presence or absence of NAFLD and smoking status was
compared using the analysis of variance test for continuous
variables and the Pearson’s χ2 test for categorical variables. The
non-parametric Kruskal-Wallis test was used to compare the
median of variables with skewed distribution (ALT, AST, GGT
and hs-CRP). A multivariate linear regression was used to evaluate associations of smoking and GGT levels. The regression
analysis was done by stratifying the presence of NAFLD and
obesity to ascertain an independent association. For all regression analyses, a hierarchical model approach was used, adjusting first for age and gender and then simultaneously adjusting
for other confounding factors (waist circumference, triglycerides, HDL-C, systolic blood pressure (SBP), fasting glucose,
LDL-C, CRP, lipid lowering and antihypertensive medications
and alcohol use). Alcohol use was quantified by the alcohol use
disorders identification test (AUDIT) score [33]. The AUDIT
score was developed and validated by the World Health Organization among men and women in different countries. We
categorized a total AUDIT score of ≥ 8 as high alcohol consumption for men and ≥ 4 for women [34]. A model including
an interaction term for HS and smoking was fitted to assess
whether smoking modified the association between HS and
GGT. All statistical analyses were performed using STATA statistical software, release 12 (College Station, TX).

Results
The characteristics of the study population were stratified by
the combination of smoking status and the presence of NAFLD
(Table 1). There were 6,354 subjects analyzed: 3,731 (59%)
non-smokers without NAFLD, 2,060 (32%) non-smokers who
had NAFLD, 324 (5%) smokers without NAFLD and 239 (4%)
smokers with NAFLD. There were statistically significant differences in demographics, anthropometric and biochemical
profiles between the four groups. Individuals with NAFLD
were more likely to be men, older and have a higher burden of
risk factors (Table 1). However, smoking combined with the
presence of NAFLD further worsened this association. Smokers with NAFLD had the highest prevalence of the MS.
Smokers with NAFLD were more likely to have the highest level of GGT levels (P < 0.001). Individuals who smoked
and had NAFLD had the highest median levels compared to
individuals who had NAFLD alone, smoked without NAFLD
or were non-smokers without NAFLD. Figures 1 and 2 show
the effect of smoking on the GGT levels in the presence and
absence of NAFLD. Although the presence of NAFLD alone
was associated with a high GGT level, it was even higher when
the presence of NAFLD is combined with a positive smoking
status (Fig. 1). Figure 2 shows similar effect of cigarette smoking on the quartiles of GGT levels when stratified by the presence of NAFLD. While non-smokers without NAFLD have
predominantly GGT levels in the lowest quartiles, there is a
steady redistribution to the higher quartiles in smokers without NAFLD, non-smokers with NAFLD and smokers with
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116 (12)
75 (8)
8
27 (24 - 32)
29 (23 - 37)
26 (19 - 36)
99 (74 - 136)
52 (14)
128 (32)
87 (9)
1 (0.5 - 0.9)
28
5.4 (4.4 - 6.3)
8
7
8
1.9 (1.3 - 3)

Obesity, BMI ≥ 30 kg/m2 (%)

Mean SBP, mm Hg (± SD)

Mean DBP, mm Hg (± SD)

HTN present (%)

Median AST, IU/L (interquartile range)

Median ALT, IU/L (interquartile range)

Median GGT, IU/L (interquartile range)

Median TG, mg/dL (interquartile range)

Mean HDL, mg/dL (± SD)

Mean LDL, mg/dL (± SD)

Mean FBG, mg/dL (± SD)

Median hs-CRP, mg/L (interquartile range)

High hs-CRP (≥ 3 mg/L) (%)

Mean uric acid, mg/dL (± SD)

Antihypertensive (%)

Lipid lowering medication (%)

Subjects with metabolic syndrome (%)

Median TG/HDL-C (interquartile range)

3.5 (2.4 - 5.4)

41

12

21

6.4 (5.7 - 7.2)

36

1.7 (0.9 - 3)

93 (12)

136 (34)

43 (10)

149 (109 - 208)

40 (30 - 56)

43 (33 - 56)

32 (28 - 39)

22

80 (7)

124 (12)

46

100 (10)

29 (4)

46 (9)

94

Smokers (-) and NAFLD
(+) (N = 2,060)

2.4 (1.5 - 3.8)

11

7

7

5.4 (4.6 - 6.4)

32

1.2 (0.5 - 2.6)

87 (9)

129 (35)

49 (13)

113 (84 - 163)

28 (21 - 43)

28 (21 - 36)

26 (23 - 31)

8

75 (8)

116 (12)

12

87 (11)

25 (3)

42 (10)

70

Smokers (+) and
NAFLD (-) (N = 324)

4.4 (2.8 - 6.5)

46

14

21

6.3 (5.6 - 7)

41

1.8 (1 - 3.5)

93 (12)

135 (34)

42 (10)

179 (124 - 240)

42 (33 - 62)

39 (31 - 53)

30 (26 - 37)

21

80 (8)

124 (12)

45

100 (9)

29 (3)

47 (9)

95

Smokers (+) and
NAFLD (+) (N = 239)

< 0.001

< 0.001

< 0.001

< 0.001

< 0.001

< 0.001

< 0.001

< 0.001

< 0.001

< 0.001

< 0.001

< 0.001

< 0.001

< 0.001

< 0.001

< 0.001

< 0.001

< 0.001

< 0.001

< 0.001

< 0.001

< 0.001

P-value

NAFLD: non-alcoholic fatty liver disease; BMI: body mass index; SD: standard deviation; SBP: systolic blood pressure; DBP: diastolic blood pressure; HTN: hypertension; ALT: alanine
aminotransferase; AST: aspartate aminotransferase; GGT: gamma-glutamyl transferase; HDL-C: high-density lipoprotein cholesterol; LDL: low-density lipoprotein; FBG: fasting blood
glucose; hs-CRP: high-sensitivity C-reactive protein; TG: triglycerides.

87 (10)
9

Mean waist circumference, cm (± SD)

42 (9)
25 (3)

Mean BMI, kg/m2 (± SD)

71

Male (%)

Mean age, years (± SD)

Smokers (-) and NAFLD
(-) (N = 3,731)

Clinical, anthropometric and biochemical characteristics

Table 1. Baseline Characteristics of Study Population
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Figure 1. Box plot of GGT levels by the combination of smoking status and presence of HS. GGT: gamma-glutamyl transferase;
HS: hepatic steatosis.

NAFLD. The GGT levels in smokers with NAFLD were predominately in the highest quartile. Figure 3 presents a similar
relationship when stratified by MS.
Table 2 presents multivariate regression of the relationship between smoking and serum GGT levels. The results are
presented from both the unadjusted and adjusted models for
possible confounders. The analysis was also stratified by the
presence of NAFLD. While there was a significant relationship
between smoking and GGT in both the combined population
and among individuals with NAFLD, the association was however not significant when NAFLD was absent. In the combined
population, the GGT level of smokers was 4.65 IU/L higher. It
was higher among individuals with NAFLD in the stratified
analysis, as the GGT level of smokers in this group was 11.12
IU/L higher. The model testing for interaction demonstrated a
statistically significant interaction of NAFLD and smoking in
the association of smoking on GGT levels. We also found a
similar association when stratified by the presence of obesity
(Table 3). Obesity interacted with the association of smoking
and the GGT levels and we noted the effect of smoking on
GGT was independent of gender (Fig. 4).

Discussion
Our study of 6,354 asymptomatic individuals assessed the impact of smoking on oxidative stress in NAFLD. While 9% of
the population were smokers, 36% had NAFLD. We demonstrated the presence of NAFLD modified the impact of cigarette smoking on GGT levels. Smokers who had NAFLD had
higher GGT levels with evidence of interaction between smoking and NAFLD on the effect of smoking on GGT levels. This
effect modification was also demonstrated with obesity and
independent of gender.
This findings support prior studies that showed a relationship between smoking, NAFLD and GGT levels [24, 35, 36].
Smoking promotes oxidative stress and has a role in the development and progression of NAFLD [24]. While liver fat is a
useful measure of visceral adiposity, it is also associated with
increased risk of CVD [19-21].
Cigarette smoking has enormous consequences on health.
It has been implicated in the development of NAFLD and
known to cause inflammation and oxidative stress. It affects in-
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Figure 2. Distribution of GGT quartiles by smoking status and presence of NAFLD. GGT: gamma-glutamyl transferase; NAFLD:
non-alcoholic fatty liver disease.

sulin resistance (IR) [35, 37, 38], which may play a role in the
development/progression of HS, a component of NAFLD [24].
Importantly, it has been demonstrated that smoking is a risk
factor for glucose intolerance and diabetes [39-41]. NAFLD
476

pathogenesis has been linked to IR and the promotion of steatogenesis by increasing the availability of free fatty acids and
glucose from adipose tissue and excess dietary intake. This
increases de novo hepatic lipogenesis, decrease fatty acid oxi-
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Figure 3. Distribution of GGT quartiles by smoking status and presence of metabolic syndrome. GGT: gamma-glutamyl transferase.

dation and decrease release of lipids from hepatocytes into circulation [18, 42]. Hamabe et al reported cigarette smoking was
an independent risk factor for the onset of HS [24]. This study
was supported by Lui et al, who reported that passive smoking
and heavy active smoking were both associated with prevalent
HS [36]. In a cross-sectional study subjects with NAFLD who
smoked had a higher frequency of the MS compared to subjects with NAFLD who did not smoke [43]. Experimental data
have also reported that smoking could worsen liver injury in
NAFLD [44]. Smoking encourages the production of activated
NADPH oxidase-induced reactive species, which enhances
oxidative stress and lipid peroxidation [24]. Oxidative stress is
a known mechanism of injury in HS [35, 45]. This study shows
that smoking increased GGT levels in general and much more
among persons with HS. As expected a similar relationship

was seen with MS and obesity. Our finding supports previous
studies that have shown that smokers had higher GGT levels
[46-48].
GGT is an enzyme responsible for the extracellular catabolism of the antioxidant glutathione [49, 50]. Although used
as a diagnostic marker for hepato-bilary disease and alcohol
abuse, strong epidemiological and clinical evidence suggests
that serum GGT is a potential biomarker for CV morbidity and
mortality [51]. Population studies reported significant independent associations between serum GGT concentrations and
risk factors, like hypertension, type 2 diabetes and stroke independent of alcohol consumption [6, 8, 10, 15, 52]. Although
the mechanism of this association is not clearly defined, it is
likely related to oxidative stress [49, 53], which could be due
to the GGT-linked pro-oxidant effect of glutathione catabolism
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Table 2. Linear Regression of the Association Between Smoking and GGT Level Stratified by NAFLD
Total (standardized coefficient)

HS+ (standardized coefficient)

HS- (standardized coefficient)

Interaction (HSsmoking)

Model 1

6.83 (3.69 - 9.96)***

10.31 (4.68 - 15.95)***

2.36 (-1.14 - 5.85)

P = 0.012

Model 2

6.51 (3.46 - 9.56)***

10.19 (4.57 - 15.81)***

2.57 (-0.83 - 5.9)

P = 0.015

Model 3

4.65 (1.61 - 7.69)**

11.12 (5.76 - 16.48)***

-0.02 (-3.59 - 3.56)

P < 0.001

*P < 0.05, **P < 0.005, ***P < 0.001. Model 1: unadjusted. Model 2: adjusted for age, gender. Model 3: model 2 + SBP, waist circumference, fasting
glucose, lipid lowering medications, hypertension meds, LDL-C, AST, alcohol consumption and C-reactive protein. GGT: gamma-glutamyl transferase; NAFLD: non-alcoholic fatty liver disease; HS: hepatic steatosis; SBP: systolic blood pressure; LDL-C: low-density lipoprotein cholesterol;
AST: aspartate aminotransferase.

Table 3. Linear Regression of the Association Between Smoking and GGT Level Stratified by Obesity
Obesity+ (standardized coefficient)

Obesity- (standardized coefficient)

Interaction (obesity-smoking)

Model 1

11.14 (3.24 - 19.03)*

4.65 (1.43 - 7.87)*

P = 0.072

Model 2

10.46 (2.64 - 18.27)*

4.60 (1.48 - 7.73)**

P = 0.096

Model 3

12.73 (5.5 - 19.96)**

1.74 (-1.45 - 4.94)

P < 0.001

*P < 0.05, **P < 0.005, ***P < 0.001. Model 1: unadjusted. Model 2: adjusted for age, gender. Model 3: model 2 + SBP, fasting glucose, lipid lowering
medications, hypertension meds, LDL-C, AST, alcohol consumption and C-reactive protein. GGT: gamma-glutamyl transferase; SBP: systolic blood
pressure; LDL-C: low-density lipoprotein cholesterol; AST: aspartate aminotransferase.

[49]. GGT notably participates in the proliferation of atheromatous plaques [50] and it is believed that oxidative stress
may be the mediating factor of the association between GGT
levels and CVD through atherosclerosis [49, 53]. GGT plays

a key role in maintaining intracellular anti-oxidant systems
through its mediation of extracellular glutathione transport into
cells. The association of elevated GGT with CVD is remarkable; Wannamethee et al described a significant relationship

Figure 4. β-coefficient of the linear regression of smoking and GGT level stratified by gender. GGT: gamma-glutamyl transferase.
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between GGT and CV events in a large prospective study with
follow-up up to 24 years [54]. Furthermore, increased GGT
levels have been demonstrated to be connected to coronary artery stenoses [1, 9]. GGT forms complexes with lipoprotein
within atheromatous lesions and in plaques [9, 50].
However, there are questions whether the CV risk of increased GGT is modifiable [1]. Although there is no convincing evidence that risk for CV events is lessened by decreasing
GGT, there are existing reports of the use of fibrates reducing
GGT concentrations in individuals with hypertriglyceridemia, improving their lipid profile [55, 56]. This may be related
to the role of fatty liver in generating increased serum GGT
and its association with an increased CV risk [1, 57]. Since
NAFLD is mostly treated by life style modifications, serum
GGT levels could also be modifiable through these measures.
Implications
Our study provides evidence that GGT, an increasingly recognized biomarker for CV risk, may be worsened by cigarette
smoking in persons with non-alcoholic liver fat. This further
re-enforces the importance of life style modifications among
persons with NAFLD. Although the presence of NAFLD is an
established risk for future CV morbidity and mortality, smoking
provides additional insult to the liver and ultimately aggravates
the risk. Since oxidative stress has been implicated in many
disease processes, including inflammation and atherosclerosis,
this study provides further motivation for physicians to emphasize both screening for smoking and smoking cessation efforts
in the routine care of individuals with HS and MS. Individuals
with elevated GGT may be candidates for NAFLD screening.

ticipants free of coronary heart disease. This has allowed for
adjustment for multiple confounding risk factors to ascertain
the relationship. The cohort size also allowed for evaluation
of the relationship within demographic and clinical subgroups.
Conclusion
Oxidative stress plays a significant step in the development
and progression of CVD. Serum GGT is an established and
measurable biomarker of oxidative stress. In this study of
asymptomatic individuals, smoking significantly raised oxidative stress as measured by GGT level among persons with
NAFLD. While elevated GGT levels are associated with both
NAFLD and CVD risk, smoking may further worsen this risk.
Although future longitudinal studies to ascertain this association are imperative, this study provides further motivation for
physicians to emphasize smoking screening and cessation in
the routine care of individuals with NAFLD and MS.
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